Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,506 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Lung Cancer Clear all
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab tesirine, Topotecan, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
28
States / cities
Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced May 21, 2026, 7:19 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Lorlatinib, Cisplatin or Carboplatin, Pemetrexed
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Asheville, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Interventions
AVID100 IV
Drug
Lead sponsor
Formation Biologics
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 21, 2026, 7:19 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
53
States / cities
Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Interventions
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Kidney Cancer, Lung Cancer
Interventions
interleukin-4 PE38KDEL cytotoxin
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced May 21, 2026, 7:19 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced May 21, 2026, 7:19 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, KRAS G12C
Interventions
Adagrasib, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
Ryan Gentzler, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Columbus, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced May 21, 2026, 7:19 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Small-cell Lung Cancer, Brain Metastases
Interventions
7t MRI
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
LY3023414, Necitumumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Chandler, Arizona • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 7:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Interventions
PRTH-101, Pembrolizumab
Biological
Lead sponsor
Incendia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 7:19 PM EDT